Aadi Bioscience CEO Brendan Delaney resigns; CFO Scott Giacobello named interim CEO

Whitehawk Therapeutics, Inc.

Brendan Delaney resigned as President, CEO, and director effective March 14, 2023, for personal reasons, not due to any disagreement.
CFO Scott Giacobello appointed Interim CEO and President effective March 15, 2023, while retaining CFO role.
Founder Neil Desai, Ph.D., continues as Executive Chairman and will assist with leadership transition.
Board has initiated a search for a permanent CEO; Giacobello's interim role ends when successor is appointed.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brendan Delaney

President and Chief Executive Officer

WHWK · Whitehawk Therapeutics, Inc.

Effective: 2023-03-14
Successor: Scott Giacobello
Filed: March 3, 2023, 6:59 PM ET

On March 2, 2023, Brendan Delaney submitted a letter to the Board of Directors (the “Board”) of Aadi Bioscience, Inc. (the “Company”) resigning from his position as the Company’s President and Chief Executive Officer (“CEO”) and as a member of the Board of Directors, effective March 14, 2023.

Appointed (interim)

Scott Giacobello

Interim Chief Executive Officer and President

WHWK · Whitehawk Therapeutics, Inc.

Effective: 2023-03-15
Filed: March 3, 2023, 6:59 PM ET

Effective March 15, 2023, the Board appointed Scott Giacobello, the Company’s Chief Financial Officer, to serve as the Company’s Interim CEO and President and principal executive officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brendan Delaney resigned as President and Chief Executive Officer at Whitehawk Therapeutics, Inc..

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

On March 2, 2023, Brendan Delaney submitted a letter to the Board of Directors (the “Board”) of Aadi Bioscience, Inc. (the “Company”) resigning from his position as the Company’s President and Chief Executive Officer (“CEO”) and as a member of the Board of Directors, effective March 14, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Giacobello was appointed as Interim Chief Executive Officer and President at Whitehawk Therapeutics, Inc..

Action: appointed
Role: Interim Chief Executive Officer and President

Exact text from the filing

Effective March 15, 2023, the Board appointed Scott Giacobello, the Company’s Chief Financial Officer, to serve as the Company’s Interim CEO and President and principal executive officer.

View on SEC.gov

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-059077

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.